Market traction BioFluidica is actively advancing liquid biopsy platforms with recent news on prenatal blood screening studies and a biomarker isolation platform, indicating growing product interest and potential pilots or collaborations in clinical research and obstetrics.

Funding momentum With over $19M in funding and a Series B2 round noted in 2022, there is an established investor backing that can be leveraged to pursue strategic partnerships, co-development opportunities, and accelerated commercial deployment.

Strategic partnerships Existing collaborations with Wright State University and Premier Health, along with publication activity, create credibility for joint development deals, KOL-led studies, and pilot programs that can be expanded into larger hospital or academic networks.

Multi-biomarker value LiquidScan and immunoaffinity microfluidics enable isolation of multiple disease biomarkers from a single sample, presenting a strong selling point for laboratories seeking multiplex tests, integrated workflows, and higher-throughput liquid biopsy solutions.

Lean operations Small team size (2–10 employees) coupled with automation hardware focus suggests opportunities to target early adopter customers with scalable, easy-to-integrate systems, professional services, and remote support offerings to drive adoption.